Drug
Pemigatinib
Pemigatinib: highest development phase Phase 2, developed by Incyte, United Therapeutics. 6 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Incyte, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pemigatinib NCT04003610 | Phase 2 | Metastatic Urothelial Carcinoma |
| Pemigatinib NCT05565794 | Phase 2 | Intrahepatic Cholangiocarcinoma |
| Pemigatinib NCT04003623 | Phase 2 | Advanced or Metastatic Solid Tumors |
| Pemigatinib NCT06906562 | Phase 2 | Advanced Pancreatic Carcinoma |
| Pemigatinib NCT02924376 | Phase 2 | Cholangiocarcinoma |
| Pemigatinib NCT02393248 | Phase 1/2 | Lung Cancer |
Latest
No recent events.
Follow Pemigatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.